• ZTE showcased solutions that enhanced token efficiency and minimized the cost-per-token through the deep synergy of various elements, including SuperPod, extremely cost-efficient inference, and AIDC with ultimate energy efficiency
• ZTE has launched the NewStart AIOS and positioned it as the "technological foundation in the AI era"
• Centered on AI-native capabilities, ZTE has driven the deep integration of AI with existing networks—through architecture upgrades and key scenario innovations—to build a next-gen communications network.

SHANGHAI, June 26, 2026 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, showcased the TCO-optimal AI factory, an AIOS-powered ecosystem spanning scenario-based applications and innovative terminals, and cutting-edge breakthroughs in AI-driven networks at MWC Shanghai 2026. Through the extreme synergy across computing, network, storage, energy, and software, as well as system-level architecture innovations, ZTE fully unlocked new momentum for token operations.

As AI agents become widespread, industry competition focus is shifting from computing power scale to token efficiency. Leveraging its end-to-end, full-stack AI capabilities, ZTE is forging a complete value chain spanning token production, services, and circulation—to enable operators, enterprises, and industry partners to unlock AI value at scale.

Building a TCO-Optimal AI Factory for More Efficient, Cost-Effective Token Production

Token efficiency is the core competitiveness in this era of inference. TCO-optimal AI factories are the key to boosting token efficiency and achieving "token freedom".

At MWC Shanghai 2026, ZTE showcased solutions that enhanced token efficiency and minimized the cost-per-token through the deep synergy of various elements, including SuperPod, extremely cost-efficient inference, and AIDC with ultimate energy efficiency.

Building on 41 years of accumulated expertise in the R&D and engineering of ultra-large-scale, complex systems, ZTE has launched its SuperPod solution. Leveraging multi-chip open collaboration design and the innovative Orthogonal Electrical eXchange (OEX) architecture, it enables plug-and-play deployment and rapid provisioning. A single rack supports 128 GPUs, with high scalability up to 16,000 GPUs, laying a foundation for high-efficiency computing in model training and inference.

Through the synergy of network, storage, and computing, as well as hardware and software, ZTE achieves extremely cost-efficient inference. With non-blocking network and Global Server Load Balancing (GSLB), ZTE's solution enables efficient coordination across computing clusters ranging from thousands to tens of thousands of GPUs, further boosting overall inference efficiency.

Moreover, ZTE has developed its AIDC solution with ultimate energy efficiency, which integrates 800V HVDC power supply, full-stack liquid cooling, and intelligent computing-electricity synergy, enabling highly efficient and low carbon operations.

From computing cluster construction and inference efficiency optimization to green operations, ZTE is steering AI factories from being compute-centric to efficiency-driven, delivering a more cost-efficient and sustainable token production system.

Developing an Innovative AIOS Technological Foundation for Smarter Token Scheduling and Closed-Loop Services

The AI factory addresses the challenge of low-cost token production, while AIOS plays a critical role in token scheduling, orchestration, and service-oriented output.

ZTE has launched the NewStart AIOS and positioned it as the "technological foundation in the AI era". Built on AIOS, Co-Claw—an enterprise-level agent platform—is fully integrated into ZTE terminals, extending AI services to production and daily life.

For enterprises, the focus is on enhancing office and R&D efficiency and enabling intelligent operations, to achieve self-evolving workflows and closed-loop decision-making.

For homes, ZTE has launched innovative terminals with different screen sizes which serve as entry points to a fully connected smart home. They can be household AI assistant, AI entertainment companion, and AI security guardian—always on, always active for an intelligent lifestyle.

For individuals, the company has introduced a new AI-native paradigm spanning AI phones, AI cloud PCs, AI smart displays, FreeScreen and more, enabling personalized recommendations, contextual responses, and immersive interactions across travel, life, and work. AI knows better and delivers enjoyable smart experiences anytime, anywhere.

Leveraging the AIOS technological foundation, Co-Claw agent platform, and a full lineup of AI devices, ZTE transforms tokens into schedulable, serviceable, and monetizable resources. This allows operators and enterprises to develop a closed–loop model for token-based services.

AI + Network, Co-Building a Future of Intelligent, Ubiquitous 6G Connectivity

6G is more than a generational leap in connectivity. It also serves as the critical infrastructure that enables efficient token circulation in the AI era.

As a key participant in global 6G research and standardization, ZTE centers around "AI+" and "SAGIN", speeding up the evolution of 6G from research to commercial use.

Regarding SAGIN, ZTE has launched industry-leading LEO satellite communication payload solutions compatible with diverse application scenarios of SAGIN for 5G-A and 6G, fostering the critical connectivity foundation for a smooth evolution from 5G-A to 6G.

As for AI-native communications, ZTE has demonstrated its GigaMIMO solution and the world's first 256 TR U6G prototype in the 6G Zone at this event. With GigaMIMO, a cornerstone technology for 6G, the solution leverages architecture innovation, computing synergy, and algorithmic breakthroughs to systematically overcome critical bottlenecks in future network capacity, coverage, and spectral efficiency, thus speeding up 6G deployment and industry evolution.

Centered on AI-native capabilities, ZTE has driven the deep integration of AI with existing networks—through architecture upgrades and key scenario innovations—to build a next-gen communications network.

The AIR MAX solution comprehensively upgrades the network architecture with AI at its core and delivers a three-tier capability system involving the AI-native infrastructure, autonomous operations, and monetization engine. Together, they empower operators in capability evolution, service transformation, operational shift, and ecosystem reshaping for the AI era.

The AI HI-NET solution delivers three key capabilities—AI-native, ultra-high-speed and lossless, and intrinsically secure, laying a solid network foundation for ubiquitous intelligent computing access, lossless wide-area connectivity, and the integration of computing, network, security, and service.

The 10G AI-Optical Network solution has been widely deployed across homes, campuses, small businesses, and other key scenarios, unlocking greater value of all-optical cities.

Meanwhile, ZTE continues to promote key scenario applications through innovations such as new calling with AI assistant, "first-class" mobile network services, ISAC for low-altitude economy, and highly autonomous networks. These efforts are made to build a more intelligent, efficient, and trustworthy connectivity foundation for the AI era.

From AI factory to AIOS, agent platform, and future networks, ZTE demonstrated an end-to-end capability system at MWC Shanghai 2026. The system covers token production, scheduling, and circulation, integrating computing, network, terminals, and agents to accelerate AI from technological breakthroughs to large-scale deployment.

The AI industry is accelerating into the inference era, where tokens have become a key measure of AI-driven value creation. Looking to the future, ZTE will work with industry partners to build AI infrastructure and ecosystems that are more efficient, inclusive, and sustainable. Together, we aim to bring AI to various industries, unlocking new growth momentum for the AI era.

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: [email protected] 

HONG KONG, June 26, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) today (Friday) welcomed the listing of the first exchange traded fund (ETF) to track the HKEX Tech 100 Index (HKEX Tech 100), launched by E Fund Management (Hong Kong) Co Limited (E Fund HK).

The E Fund (HK) HKEX Tech 100 Index ETF (Stock Code: 3456) is the first investment product based on an HKEX-branded equity index, marking an important milestone as the Group builds its index business to facilitate investor access to capital markets.

The ETF's listing coincides with the 26th anniversary of HKEX's debut as a listed company — a fitting occasion to celebrate a new chapter in the Group's index business, alongside 26 years of innovation, vibrancy and growth. Since becoming a publicly traded company in 2000, HKEX has evolved from a local exchange into a leading global market operator and superconnector, committed to continuously enriching its product ecosystem and connecting capital with opportunity.

HKEX Chief Executive Officer Bonnie Y Chan said: "We are delighted to celebrate the listing of the first ETF based on an HKEX branded index. This ETF – launched by E Fund HK – combines a representative Hong Kong technology benchmark with a widely accessible investment vehicle, supporting investors in diversifying their portfolios and accessing the growth opportunities offered by Hong Kong listed technology companies. This listing also marks a milestone for HKEX's index business and underscores our commitment to continuously developing new and relevant products to better serve the evolving needs of global investors."

Chairperson of E Fund Management Co Ltd Liu Xiaoyan stated: "As the first institution to launch an E Fund (HK) HKEX Tech100 Index ETF (3456) tracking the HKEX Tech 100 Index, E Fund is deeply honored. This is not only an important step in product innovation, but also a key practice in leveraging Hong Kong's 'super connector' advantage to deepen our internationalization strategy. The index brings together 100 of the high-potential technology companies in the Hong Kong market, and we hope to open an efficient gateway for global investors to participate in the future of China's technology sector. Looking ahead, we will continue to drive further product innovation, actively serve the diversified asset allocation needs of global investors, and contribute to the continued prosperity and openness of Hong Kong's financial market."

The HKEX Tech 100 is a broad-based index tracking the performance of the 100 largest technology related companies by market capitalisation listed in Hong Kong, spanning a range of innovative and new economy sectors. The index comprises stocks eligible for Southbound trading under Stock Connect and is designed to address the growing market demand for diversified exposure to the technology sector.

More recently, HKEX has also launched the HKEX Bursa Malaysia Large Cap Index, the HKEX KRX Semiconductor Index and the HKEX Tech & US Tech 100 Index, to further strengthen market connectivity across Asia and beyond. HKEX will continue to work closely with asset managers, index users and market participants to enrich its index ecosystem and support the development of innovative index based products, reinforcing Hong Kong's position as an international financial centre and a key gateway connecting the Chinese Mainland and global markets.

About HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is a publicly-traded company (HKEX Stock Code:388) and one of the world's leading global exchange groups, offering a range of equity, derivative, commodity, fixed income and other financial markets, products and services, including the London Metal Exchange.

As a superconnector and gateway between East and West, HKEX facilitates the two-way flow of capital, ideas and dialogue between China and the rest of the world, through its pioneering Connect schemes, increasingly diversified product ecosystem and its deep, liquid and international markets.

HKEX is a purpose-led organisation which, across its business and through the work of HKEX Foundation, seeks to connect, promote and progress its markets and the communities it supports for the prosperity of all.

www.hkexgroup.com 

JAKARTA, Indonesia, June 26, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology company Tencent, has successfully assisted leading Indonesian telecom operator XLSMART in completing a large-scale public cloud migration transformation project. The transformation was driven by XLSMART's long-term digital modernization strategy, with Tencent Cloud serving as the strategic cloud technology partner. Spanning four and a half months, the project marks a pioneering industry practice of leveraging artificial intelligence (AI) to enhance cloud migration efficiency.

During the process, Tencent Cloud developed over 20 cloud migration "Skills" powered jointly by Tencent's coding agent, CodeBuddy, and its AI agent workspace, WorkBuddy. From resource discovery to final cutover, Tencent's AI capabilities boosted the migration team's overall efficiency significantly. This large-scale operation seamlessly migrated 1,200 microservices, 1,100 APIs, and 900 business interfaces, securely transitioning over 15 TB of core data assets.

Formed in April 2025 through the milestone merger of XL Axiata and Smartfren, XLSMART has emerged as a premier telecom operator in Indonesia. Jointly owned by Indonesia's Sinarmas Group and Malaysia's Axiata Group, the company serves a massive user base of over 69 million nationwide, spanning mobile communications, home broadband, and enterprise digital services. However, as XLSMART navigates its post-merger integration, it faced steep technical hurdles: more than 60 core applications and 1,200 microservices were scattered across fragmented multi-cloud platforms, impeding unified operations and management. To address this complexity, XLSMART pivoted in December 2025, kicking off its strategic cloud transformation project.

The challenges, however, extended far beyond technology into the organizational realm. More than the majority of the target applications required a complete redesign or rebuild, a monumental task split across over ten third-party vendors. Managing this intricate web of multi-vendor collaboration and cross-language coordination elevated the project's complexity well beyond a standard migration. Rejecting a superficial 'lift-and-shift' approach, XLSMART executed a deliberate strategy: a comprehensive architectural audit to determine what to retain, modify, or optimize. While this deep overhaul significantly compounded the pressure under a compressed timeline, driving operational efficiency became the lynchpin of the project's success.

Instead of confining AI to isolated tasks, Tencent Cloud integrated AI capabilities across every phase of the project, including service discovery, architecture design, environment deployment, migration cutover, and system monitoring. Utilizing its tools like TokenHub, CodeBuddy, and WorkBuddy, tasks that traditionally required months of manual labor were compressed into weeks or even days. The portfolio of over 20 Skills developed during the migration process has since been consolidated into a reusable AI migration platform.

To tackle resource discovery and architecture analysis—traditionally the most labor-intensive phase of migration—Tencent Cloud deployed two core "Skills." The first automatically scans cross-account environments, mapping hundreds of legacy resource specifications directly to Tencent Cloud configurations to generate deployable design blueprints. The second infers application architectures from discovered assets, instantaneously producing Low-Level Design (LLD) spec sheets and visual architecture diagrams. This shifted the engineers' role from the tedious grind of manual Excel logging to high-value review and fine-tuning. Combined with supporting tools for Terraform conversion, SDK adaptation, and automated cutover playbook generation, XLSMART unified the entire lifecycle— from discovery, design, and implementation to cutover—into a single AI-driven pipeline, yielding a significant boost in operational efficiency.

During the migration, Tencent Cloud delivered over 20 core products to XLSMART, including databases, containers, security solutions, and intelligent advisors, while completing more than 200 feature developments—ensuring full adaptation to the overseas technology ecosystem and local cloud usage habits. In addition, the team introduced mature capabilities such as Database Claw, which significantly enhances database operations efficiency through agent-based capabilities.

Through the close collaboration of both teams, XLSMART successfully executed a seamless, zero-downtime migration of 1,200 microservices, 1,100 APIs, and 900 business interfaces in a mere 4.5 months. To guarantee enterprise-grade resilience, Tencent Cloud went far beyond standard testing protocols, conducting deep-dive security scanning and rigorous infrastructure hardening tailored specifically to safeguard XLSMART's mission-critical applications.

Poshu Yeung, Senior Vice President of Tencent Cloud, Head of Tencent Cloud International, said, "This batch of cloud migration Skills has now been consolidated into a reusable migration platform, which will be continuously applied and refined in subsequent projects. Partnering with XLSMART on this industry-benchmark project has been a privilege, and we will continue to provide solid technical support to anchor their next phase of growth."

Yessie D. Yosetya, Director and Chief Information & Technology Officer of XLSMART, said, "This project is more than a cloud migration. It establishes a stronger digital foundation that enables XLSMART to innovate faster, improve operational resilience, and continuously enhance customer experience. Together with Tencent Cloud, we have demonstrated how strong collaboration can accelerate large-scale transformation while maintaining service reliability."

Currently, Tencent Cloud's global footprint spans more than 80 markets and regions, backed by four consecutive years of robust, double-digit growth. Leveraging its global infrastructure and integrated hardware-software synergy, Tencent Cloud delivers market-leading solutions to worldwide enterprises, empowering their digital transformation and operational excellence. In Indonesia and across Southeast Asia, Tencent Cloud remains dedicated to deepening its local presence by expanding public cloud coverage and cultivating a thriving partner ecosystem. Moving forward, Tencent Cloud is set to deepen its alliances with international partners like Sinarmas Group and Axiata Group, anchoring a sustainable and mutually beneficial digital future.

About Tencent Cloud
Tencent Cloud, one of the world's leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation. 

上海2026年6月26日 /美通社/ -- 雲頂新耀（HKEX 1952.HK，以下簡稱「公司」），一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈中國國家藥品監督管理局（NMPA）已正式受理第三代PCSK9抑制劑樂瑞泊^® （LEROCHOL^®, 萊達西貝普，Lerodalcibep）的生物製品上市許可申請（BLA），在飲食控制和運動的基礎上，用於降低成人高膽固醇血症（包括雜合子型家族性高膽固醇血症[HeFH]）患者的低密度脂蛋白膽固醇（LDL-C）水平。此次受理按計劃如期達成，是公司高效執行既定臨床開發與註冊戰略的又一有力體現，標誌著2026年度關鍵研發里程碑的穩步兌現。

樂瑞泊^®是一款新型第三代小分子量的重組融合蛋白治療藥物，由PCSK9結合域（Adnectin）和人血清白蛋白（HSA）組成，分子量約為77 kDa，並以皮摩爾級別的親和力與PCSK9結合。樂瑞泊^®的推薦劑量為每月一次皮下注射300毫克。在使用前，樂瑞泊^®可在不超過25°C的室溫下保存長達3個月。這些特點使其有望在現有已獲批PCSK9抑制劑中實現差異化，並具備同類最佳潛力。

北京大學第一醫院心內科首席專家霍勇表示：「樂瑞泊^®的生物製品上市許可申請獲得NMPA受理，為廣大患者帶來了新的希望。大量研究證實LDL-C是動脈粥樣硬化性心血管疾病（ASCVD）最重要且容易改變的致病性危險因素之一，已被國內外血脂管理指南確定為防治該疾病的首要干預靶點，在現有降脂療法下，大部分心血管疾病患者或高風險人群（包括家族性高膽固醇血症）仍未能達到最新指南推薦的 LDL-C 控制目標，臨床亟需更有效的創新療法。

中國Ⅲ期臨床試驗結果顯示，樂瑞泊^®在治療期間顯著降低中國高膽固醇血症患者的LDL-C水平，同時安全性和耐受性良好。結合其每月一次的小劑量單劑皮下注射給藥方案，以及在室溫下可穩定保存長達3個月的優勢，樂瑞泊^®將為患者血脂管理的長期居家或出行期間用藥提供一種更有效、便捷的治療選擇。期待該藥物早日獲批，為更多患者帶來獲益。」

雲頂新耀首席執行官羅永慶先生表示：「此次BLA申請獲得NMPA受理，是樂瑞泊^®在中國商業化進程中的重要一步。

心血管疾病仍然是全球及中國的主要死亡原因。中國血脂異常人群規模約4億，接受降脂治療的比例僅約14%^[1]，反映出滲透率偏低及顯著的未滿足醫療需求。

作為潛在同類最佳PCSK9抑制劑，樂瑞泊^®憑借其顯著的降脂療效、良好安全性和便捷的給藥優勢，可更好滿足患者長期居家血脂管理需求，提供新的治療選擇。樂瑞泊^®有望於2027年在中國大陸獲得批准並上市。我們將持續推進其在大中華區的可及性，力爭早日惠及更多患者。」

樂瑞泊^®此次申請是基於其在全球範圍內開展的多項大型臨床試驗以及在中國進行的關鍵註冊性Ⅲ期臨床試驗的結果。在總計超過2,900例患者入組的多項全球大型Ⅲ期臨床試驗中，結果顯示，樂瑞泊^®可使心血管疾病(CVD)患者或極高/高風險族群的LDL-C持續降低≥60%，並使LDL-C升幅更嚴重的（包括HeFH）患者降低59%。中國Ⅲ期臨床試驗結果顯示，樂瑞泊^®300 mg每月一次皮下注射顯著降低了患者LDL-C水平，與安慰劑相比第12周降幅達65.9%，第10和第12周平均降幅為67.0%。同時，超過95%的患者成功達到了中國血脂管理指南推薦的LDL-C目標^[2]。

此前，樂瑞泊^®的生物製品上市許可申請（BLA）已獲得美國食品藥品監督管理局批准，並已向歐洲藥品管理局遞交上市許可申請。

關於樂瑞泊^®（LEROCHOL^®，萊達西貝普，Lerodalcibep）

樂瑞泊^®是一款新型第三代分子量較小的重組融合蛋白治療藥物，由PCSK9結合域（Adnectin）和人血清白蛋白（HSA）組成，分子量約為77 kDa，並以皮摩爾級別的親和力與PCSK9結合。樂瑞泊^®的推薦劑量為每月一次皮下注射300毫克（1.2毫升）。在使用前，樂瑞泊^®可在不超過25°C（77°F）的室溫下保存長達3個月。這些特點使其有望在現有已獲批PCSK9抑制劑中實現差異化，並具備同類最佳潛力。

萊達西貝普的生物製品上市許可申請已於2025年12月12日獲得美國食品藥品監督管理局批准，作為一款前蛋白轉化酶枯草溶菌素9（PCSK9）抑制劑，在飲食控制和運動的基礎上，用於降低成人高膽固醇血症（包括HeFH）患者的低密度脂蛋白膽固醇水平。萊達西貝普已向歐洲藥品管理局和中國國家藥品監督管理局遞交上市許可申請，目前正處於審評階段。

關於雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、美國及歐盟標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

關於LIB Therapeutics Inc.
LIB Therapeutics 是一家處於商業化階段的私人控股生物製藥公司，致力於開發並提供創新、高效且安全的治療方案，幫助數以百萬計的心血管疾病及家族性高膽固醇血症患者實現其低密度脂蛋白膽固醇（LDL-C）控制目標。欲瞭解更多信息，請訪問：www.libtherapeutics.com。

前瞻性聲明

本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

參考文獻

[1]. 中國心血管健康與疾病報告2022-2024

[2]. Chen, B, Pei, Z, HUANG, Z. et al. 26-A-8397-ACC EFFICACY AND SAFETY OF LERODALCIBEP IN CHINESE PATIENTS WITH HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL. JACC. 2026 Apr, 87 (13_Supplement) A166.

OpenAI is inclined to postpone its IPO to next year, as the company’s banking advisers warned that recent sharp swings in technology stocks and in shares of Space Exploration Technologies Corp. (SPCX.US) following its listing could dampen retail investors’ enthusiasm for an OpenAI IPO, New York Times, citing sources, reported.

The news weighed on SoftBank (9984.JP), whose shares once plunged nearly 13% this morning (26th) and closed down more than 12% at midday. SoftBank’s investment in OpenAI is expected to reach approximately USD65 billion by October. The market has been anticipating that an OpenAI listing would generate substantial gains for SoftBank.

OpenAI CEO Sam Altman urged advisers, including bankers and lawyers, to set a target valuation of USD1 trillion for the company, report said.
~

AASTOCKS Financial News
Website: www.aastocks.com

Apple Inc. (AAPL.US) said that it announced price increases for Mac, iPad and home devices, in light of memory chip woes which prompt soaring prices. Its share price closed down 6.1%. Apple-related concept stocks listed in Hong Kong declined broadly.

AAC TECH (02018.HK) opened 1.53% lower today, hitting a trough of HKD42.6. It last stood at HKD42.74, down 6.48%, with 3.5167 million shares traded, involving HKD152 million.

SUNNY OPTICAL (02382.HK) announced plans to issue RMB-denominated bonds. It opened 2.99% lower today, hitting a trough of HKD58.3. It last stood at HKD58.9, down 12.09%, with 19.4982 million shares traded, involving HKD1.188 billion.

COWELL (01415.HK) opened 1% lower today, hitting a trough of HKD22.02. It last printed at HKD22.2, down 7.65%, with 2.621 million shares traded, involving HKD59.0832 million.

TONGDA GROUP (00698.HK) opened 6.7% lower today, hitting a trough of HKD1.74. It last traded at HKD1.74, down 10.31%, with 151,400 shares traded, involving HKD273,700.

FIH (02038.HK) opened 0.99% lower today, hitting a trough of HKD20.78. It last stood at HKD21, down 5.49%, with 1.2525 million shares traded, involving HKD26.4175 million.

FIT HON TENG (06088.HK) opened 2.51% lower today, hitting a trough of HKD6.66. It last quoted at HKD6.84, down 9.64%, with 49.627 million shares traded, involving HKD340 million.
~

AASTOCKS Financial News
Website: www.aastocks.com

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL^® (lerodalcibep), a third-generation PCSK9 inhibitor,  for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

The on-schedule acceptance underscores the Company's disciplined execution of its clinical and regulatory strategy, and marks another key R&D milestone for 2026.

LEROCHOL^® is a novel, third-generation small recombinant fusion protein therapeutic agent comprised of a proprotein convertase subtilisin/kexin type 9 (PCSK9)-binding domain (Adnectin) and human serum albumin (HSA) with an approximate molecular weight of 77 kDa and binds PCSK9 with picomolar affinity. The recommended dosage of LEROCHOL^® is 300 mg administered subcutaneously once monthly. LEROCHOL^® may be kept at room temperature up to 25°C for up to 3 months prior to use. These features make LEROCHOL^® a unique alternative to other PCSK9 inhibitors. 

"The NMPA's acceptance of the BLA for LEROCHOL^® brings renewed hope to patients. Extensive studies have confirmed that LDL-C is one of the most critical and modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). It has been identified as the primary intervention target for ASCVD prevention and treatment in both domestic and international lipid management guidelines. Despite the availability of existing lipid-lowering therapies, many patients with or at risk of CVD, including those with familial hypercholesterolemia (FH), still fail to achieve updated guideline-recommended LDL-C targets, highlighting the urgent need for more innovative treatment options," said Professor Yong Huo, the leading principal investigator, Chief Cardiology Expert from Peking University First Hospital. "Results from the Phase 3 clinical trial demonstrated that Lerodalcibep significantly reduced LDL-C with a favorable safety and tolerability profile in Chinese patients with hypercholesterolemia. Its convenient monthly, single small-dose subcutaneous regimen, and up to 3-month room temperature stability address a significant unmet need in long-term lipid management for patients at home or during travel. We hope LEROCHOL^® will soon be available to more patients."

"The BLA acceptance by the NMPA represents a significant step toward the commercialization of LEROCHOL^® in Greater China," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "CVD remains the leading cause of death globally and in China. Despite an estimated 400 million individuals in China with dyslipidemia, only around 14% receive lipid-lowering treatment^[1], reflecting low penetration and significant unmet medical need.

As a potential best-in-class PCSK9 inhibitor, LEROCHOL^® offers a novel treatment option with its robust lipid-lowering efficacy and favorable safety. It also provides extended room-temperature stability, enabling more convenient storage and travel, and supporting long-term lipid management at home. With the potential for approval in mainland China in 2027, we will continue to expand access to LEROCHOL^® across Greater China, helping more patients benefit from this innovative therapy."

The application is based on results from multiple global clinical trials as well as Phase 3 clinical trial in China. In global clinical trials, LEROCHOL^® demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of CVD and 59% in those with HeFH who have more severe LDL-C elevations. Results from the Phase 3 clinical trial of LEROCHOL^® in China showed that LEROCHOL^® significantly reduces LDL-C levels. Mean placebo adjusted LDL-C reductions from baseline in the co-primary end-points, were 65.9% at week 12 and 67.0% for the mean of weeks 10 and 12. Over 95% of participants on LEROCHOL^® achieved dual Chinese lipid management guideline LDL-C targets^[2].

The U.S. Food and Drug Administration (FDA) has approved LEROCHOL^®, and it is currently under regulatory review by the European Medicines Agency (EMA).

About LEROCHOL^®(lerodalcibep-liga)
Lerodalcibep (LEROCHOL^®) received marketing approval by FDA on December 12, 2025 and is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep's Marketing Authorization Applications to the European Medicines Agency and China's National Medical Products Administration are currently under regulatory review.

LEROCHOL^® is a novel, third-generation small recombinant fusion protein therapeutic agent comprised of a proprotein convertase subtilisin/kexin type 9 (PCSK9)-binding domain (Adnectin) and human serum albumin (HSA) with an approximate molecular weight of 77 kDa and binds PCSK9 with picomolar affinity. The recommended dosage of LEROCHOL^® is 300 mg (1.2mL) administered subcutaneously once monthly. LEROCHOL^® may be kept at room temperature up to 25°C (77°F) for up to 3 months prior to use. These features make Lerodalcibep a unique alternative to other PCSK9 inhibitors.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

About LIB Therapeutics, Inc.

LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company dedicated to bringing novel, highly effective, and safe therapies to help the millions of people with cardiovascular disease and familial hypercholesterolemia finally achieve their LDL-C goals. For more information, please visit: www.libtherapeutics.com.

Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects,""anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

References

[1].  China Cardiovascular Health and Disease Report 2022-2024
[2].  Chen, B, Pei, Z, HUANG, Z. et al. 26-A-8397-ACC EFFICACY AND SAFETY OF LERODALCIBEP IN CHINESE PATIENTS WITH HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL. JACC. 2026 Apr, 87 (13_Supplement) A166.

Apple Inc. (AAPL.US) shares slumped 6.1% overnight (25th), marking the steepest downfall among S&P 500 and DJIA constituents, after the company announced that rising memory and storage chip costs would prompt higher prices for iPad and MacBook products.

In Hong Kong, the iPad Air 128GB recorded the largest increase, with the price rising from HKD4,599 to HKD5,999, representing an increase of 30.4%.

The price of MacBook Neo rose by 14.6%, or HKD700, to HKD5,499; that of MacBook Air 512GB added by 16.7% to HKD10,499; and that of iPad mini climbed by 21.1% to HKD4,599.

Apple stated that the consumer electronics industry is facing challenges. Rapid expansion of AI data centers has driven exceptionally strong demand for memory and storage chips, making it necessary to raise prices for certain products, with the possibility of further price increases in the future.
~

AASTOCKS Financial News
Website: www.aastocks.com

財務摘要

香港2026年6月25日 /美通社/ -- 維他奶國際集團有限公司（「維他奶」或「公司」，連同其附屬公司為「集團」，股份代號：00345）今日公佈其截至2026 年3月31日止之全年業績。

於2025/2026財政年度期間，集團收入減少3%，主要由於中國內地業務受到傳統零售渠道疲弱表現影響所致，惟全渠道的增長令人鼓舞並抵銷部分有關影響。於集團層面，維他奶透過將更多生產整合至東莞廠房，提升資產使用率及廠房效率。儘管 Vitasoy Australia Products Pty. Ltd. 錄得減值支出（「VAP減值」），公司亦透過出售維他奶（上海）有限公司持有的土地及樓宇（「VSL出售事項」）強化資產負債表。

集團經營溢利增加18%，得益於VSL出售事項收益及營運過程中有效合理控制經營成本，惟毛利下降及VAP減值虧損抵銷部分有關增幅。撇除VSL出售事項及VAP減值，經營溢利增加4%。

維他奶國際集團有限公司執行主席羅友禮先生今天於業績發佈會上表示：「對維他奶而言，2025/2026財政年度是充滿變化的一年，市場競爭環境激烈，尤以中國內地為甚，同時不明朗地緣政治因素亦有所加劇。面對充滿挑戰的環境，集團專注推進營運模式演變及提升組織架構能力，為未來實現持續增長作好準備。」

基於集團的財務表現，並考慮到集團的現金狀況以及維持穩定派息率的政策，董事會已建議派發2025/2026財政年度末期股息每股普通股港幣13.5仙，該建議已反映VSL出售事項的影響，惟須待股東於將於2026年8月24日舉行的股東週年大會上批准。連同中期股息每股普通股港幣4.0仙，2025/2026財政年度的股息總額為每股普通股港幣17.5仙（2024/2025財政年度：每股普通股14.2港仙）。

除一般股息派發外，公司於該財政年度亦進行股份回購計劃，以提升回報並為股東創造額外價值。

中國內地 —
擴大植物奶及豆奶市場份額；穩定有糖茶品類市場份額並強化組織架構能力，以推動下一階段增長

中國內地收入下降5%，原因是令人鼓舞的新興全渠道增長不足以抵銷傳統零售渠道的下跌。撇除VSL出售事項，經營溢利率為穩健的9%。

為應對市場及渠道動態的演變，維他奶強化銷售組織架構，以在下滑的傳統零售渠道爭取改善表現，同時透過產品差異化及定制化加快新全渠道增長。

為提升營運效率並支持長遠發展，維他奶整合生產設施，以提高使用率及規模經濟。作為城中村改造項目的一部分，集團將維他奶上海持有的閒置土地及樓宇出售予松江區人民政府，並實現收益人民幣1億3千7百萬元（相當於港幣1億5千1百萬元）。該交易進一步提升經營溢利並強化集團的資產負債表。

維他奶亦重塑各項能力，以支持可持續增長。透過強化執行能力，並將組織架構與新興渠道的需求對齊，維他奶正為中國內地更堅韌的增長建立更穩固基礎。

香港業務（香港特別行政區^[1]、澳門特別行政區^[2]及出口）—
因澳門特別行政區及維他天地業務疲弱表現而導致收入及盈利能力下降；在香港特別行政區保持領先市場份額及穩健表現

年內收入下降3%，主要由於澳門特別行政區及維他天地業務表現未如理想。儘管如此，維他奶透過嚴謹的產品策略、卓越營運能力及其穩定執行，在香港特別行政區這核心市場的植物奶及茶分部維持領先地位。

澳洲及新西蘭 —
淨銷售收入創新高，虧損大幅收窄，惟受減值支出負面影響

2025/2026財政年度期間，澳洲及新西蘭的淨銷售收入增長4%並創下新高。澳洲業務經歷一年業務根基重建後，目前營運已大致穩定，重點已轉向增長及持續改善。積極促銷計劃帶動市場份額回升，而家庭滲透率亦有所增長。倘撇除VAP減值，受惠於有利匯率變動以及運輸及間接成本節省，經營虧損於年內減少澳幣7百萬元（相當於港幣3千7百萬元）至澳幣8百萬元（相當於港幣4千萬元）。

產品創新仍是主要推動力，包括於第四季度在所有主要的超級市場推出一公升膠樽裝燕麥口味系列產品，其包含三款口味：朱古力布朗尼、冰拿鐵及海鹽焦糖。

年內，由於VAP近年仍處於虧損狀態以及復甦時間延長，故確認物業、廠房及設備減值澳幣1千9百萬元（相當於港幣9千8百萬元）。

新加坡 —
業務轉虧為盈，豆腐銷售強勁增長

新加坡收入增加9%，主要受豆腐銷售強勁增長帶動。新加坡業務透過擴大銷量、產品及成本優化、原材料成本下降及運輸費用節省，成功轉虧為盈。

菲律賓（非綜合入賬合營公司） —
在快速增長的植物飲品類別下強化品牌價值

在集團與 Universal Robina Corporation 的合營公司中，豆奶、杏仁奶及燕麥奶全線產品組合於年內繼續發展，家庭裝產品業務展現可持續增長動力。

整體展望

展望未來，集團致力拓展業務並提高收入增長，同時維持營運效率。

在中國內地，維他奶已具備所需商業能力並準備進入下一階段增長。更優秀強大的銷售團隊將繼續提升傳統零售渠道市場份額，同時透過產品差異化及定制化方針加快新興全渠道增長。

在香港業務方面，維他奶將繼續透過產品創新，並輔以澳門特別行政區業務在新領導團隊下的改善，推進具規模的領先地位。

澳洲及新西蘭以及新加坡將繼續推動銷售增長，同時透過高效成本管理措施改善盈利能力。

憑藉正面的品牌價值、穩健的核心產品組合及持續創新，集團在各市場均具備有利條件，可實現長遠價值及增長。維他奶全面的架構組織能力，加上以植物為本的食品及飲品的國際認知度不斷增長，為成功奠定堅實基礎。維他奶對長遠潛力充滿信心，並致力實現可持續增長。

詳情請參閱以下文件：

• 截至2026年3月31日止之全年業績公告：
  按此
• 下載圖片：
  按此

關於維他奶

維他奶國際集團有限公司是一間專注植物食品及飲品的生產及分銷商，總部設於中國香港。自維他奶於 1940 年由羅桂祥博士創立以來，一直致力以各種高品質產品，以營養、美味及可持續發展作為開拓產品方針，從而推廣可持續的營養，並重視社會責任及致力回饋社會。目前，維他奶旗下產品行銷全球約 40 個市場，在中國（包括中國內地及香港特別行政區）、澳洲、新加坡及菲律賓設有營運基地。

維他奶國際集團有限公司（00345.HK）在香港聯合交易所主板上市，並獲納入多個指數類別，包括摩根士丹利資本國際指數（MSCI） 香港小型股指數及恒生可持續發展企業基準指數。

維他奶公司網站：www.vitasoy.com

附註：
^[1]「香港特別行政區」指中華人民共和國香港特別行政區。
^[2]「澳門特別行政區」指中華人民共和國澳門特別行政區。

Financial Highlights

HONG KONG, June 25, 2026 /PRNewswire/ -- Vitasoy International Holdings Limited ("Vitasoy" or the "Company", together with its subsidiaries, the "Group", Stock Code: 00345) today announced its annual results for the year ended 31 March 2026 ("the year").

During the year, revenue of the Group decreased by 3%, primarily due to weaker performance in the Chinese Mainland where the business was affected by softness in the general trade channel, partially mitigated by encouraging growth in the Omni channels. At the Group level, Vitasoy improved asset utilisation and plant efficiency by consolidating more production at the Dongguan factory. Vitasoy also strengthened the balance sheet through the disposal of land and buildings held by Vitasoy (Shanghai) Company Limited ("VSL Disposal"), despite the impairment charge recorded by Vitasoy Australia Products Pty. Ltd. ("VAP Impairment").

Profit from operations increased by 18%, driven by a gain from the VSL Disposal and effective operating cost rationalisation in the operations, partially offset by lower gross profit and the VAP Impairment losses. Excluding the VSL Disposal and VAP Impairment, profit from operations increased by 4%.

Mr. Winston Yau-lai Lo, Executive Chairman of Vitasoy International Holdings Limited, said at the press conference today, "For Vitasoy, FY2025/2026 was a dynamic year marked by highly competitive market conditions, particularly in the Chinese Mainland, as well as heightened geopolitical uncertainty. Against this challenging backdrop, the Group focused on evolving its operating model and upgrading its organisational capabilities to prepare for a future of sustained growth."

Based on the Group's financial performance, and having regard to the Group's cash position and its policy of maintaining a stable payout ratio, the Board of Directors has proposed a final dividend of HK$13.5 cents per ordinary share for FY2025/2026, which reflects the VSL Disposal, subject to the shareholders' approval at the Annual General Meeting to be held on 24 August 2026. Together with the interim dividend of HK$4.0 cents per ordinary share, this brings the total dividend for FY2025/2026 to HK$17.5 cents per ordinary share (FY2024/2025 annual: HK$14.2 cents per ordinary share).

In addition to the usual dividend distribution, the Company also undertook a share buy-back programme during the financial year to enhance returns and create additional value for shareholders.

Chinese Mainland –
Growing market share in plant milk and soy milk; stabilising sweetened tea market share and strengthening organisational capability to deliver the next phase of growth 

Revenues in Chinese Mainland declined by 5%, as the encouraging growth in new Omni channels was more than offset by the decline in the general trade channel. The operating profit margin excluding the VSL Disposal was a solid 9%.

In response to evolving market and channel dynamics, Vitasoy strengthened the sales organisation to secure improved performance in the declining general trade channel, while accelerating growth in the new Omni channel through differentiation and customisation.

To improve operational efficiency and support long-term development, Vitasoy consolidated the production facilities to enhance utilisation and economies of scale. The Group disposed of the idle land and buildings held by Vitasoy (Shanghai) Company Limited to the government of Songjiang District as part of the Land Plot Urban Village Renovation Project and realised a gain of RMB137 million (equivalent to HK$151 million). This transaction further improved profit from operations and strengthened the Group's balance sheet.

Vitasoy also reset the capabilities in support of sustainable growth. By strengthening the execution capability and aligning the organisation with the requirements of the new winning channels, Vitasoy is building a stronger foundation for more resilient growth in the Chinese Mainland.

Hong Kong Operation (Hong Kong SAR^[1], Macau SAR^[2] and Exports) –
Decline in revenue and profitability due to soft performance in the Macau SAR and Vitaland Group; retaining leadership share and solid performance in the Hong Kong SAR

Revenue declined by 3% during the year, mainly due to underperformance in the Macau SAR and Vitaland businesses. Nevertheless, Vitasoy maintained the leading position in the plant milk and tea segments in the core Hong Kong SAR market through disciplined product strategy, operational excellence and consistent execution.

Australia and New Zealand –
Record net sales revenue and significant loss reduction but negatively affected by impairment charges

FY2025/2026 delivered record net sales revenue performance across Australia and New Zealand, with net revenue increasing by 4%. Following a year of rebuilding the foundation for the Australian business, operations have now broadly stabilised, with the focus shifting to growth and continuous improvement. Market share was regained and household penetration increased as a result of aggressive promotion programmes. Operating loss, if excluding the VAP Impairment, was reduced by AUD7 million (equivalent to HK$37 million) during the year to AUD8 million (equivalent to HK$40 million), supported by favourable exchange movements and savings in transportation and overhead costs.

Product innovation remained a key driver, including the launch of the 1L Oat Flavour Range PET in the fourth quarter across all major grocery customers, comprising three SKUs: Chocolate Brownie, Iced Latte and Salted Caramel.

During the year, an impairment of AUD19 million (equivalent to HK$98 million) on property, plant and equipment was recognised since VAP remained in a loss position in recent years and faced a delay in recovery.

Singapore – 
Business turns profitable with strong growth in tofu sales

Revenue in Singapore increased by 9%, mainly driven by strong growth in tofu sales. Business in Singapore is turning around and profitability has been restored through volume expansion, product and cost optimisation, lower raw material costs and transportation savings.

The Philippines (Non-Consolidated Joint Venture) –
Strengthening brand equity in the fast-growing plant-base category

In the joint venture with Universal Robina Corporation, the complete portfolio of soy, almond and oat continued to develop during the year, with the multi-serve business demonstrating sustainable growth momentum.

Business Outlook

Looking ahead, the Group is committed to expanding the business and increasing revenue growth, while maintaining operational efficiency.

In the Chinese Mainland, Vitasoy's commercial capability is now ready for the next phase of growth. A stronger sales team will continue growing market share in general trade channels while accelerating growth in new Omni channels via differentiation and customisation.

In the Hong Kong Operation, Vitasoy will continue advancing its scale leadership through product innovation, complemented by improving the Macau SAR business under new leadership.

Both Australia & New Zealand and Singapore will continue to drive sales growth while improving profitability via efficient cost management measures.

The Group remains well positioned to deliver long-term value and growth across the markets, bolstered by the positive brand equity, robust core product portfolio and ongoing innovation. Vitasoy's comprehensive organisational capabilities, combined with the international presence in the growing plant-based food and beverages market, provide a solid foundation for success. Vitasoy is confident in the long-term potential and committed to delivering sustainable growth.

For more details, please refer to the following documents:

• Announcement of results for the year ended 31 March 2026:
  Link
  
  
• Photos download:
  Link

About Vitasoy

Vitasoy International Holdings Limited is a leading manufacturer and distributor of plant-based food and beverages. Established in 1940 by the late Dr. Kwee-seong Lo in Hong Kong China, the Company strives to promote sustainable plant-based nutrition through provision of a variety of high-quality products with Nutrition, Taste and Sustainability as the guidelines for its portfolio offerings. Currently, Vitasoy has operations in China, including the Chinese Mainland and Hong Kong Special Administrative Region, Australia, Singapore and the Philippines. Its products are available in about 40 markets worldwide.

Vitasoy is listed on the main board of the Hong Kong Stock Exchange (00345.HK) and included as a constituent of Morgan Stanley Capital International (MSCI) Hong Kong Small Cap Index, and Hang Seng Corporate Sustainability Benchmark Index, among others.     

Vitasoy website: www.vitasoy.com